Esófago de Barrett: experiencia de 10 años en un centro de tercer nivel en México

Valdovinos-Andraca, Francisco; Bernal-Méndez, Ambrosio Rafael; Barreto-Zúñiga, Rafael; Briseño-García, D.; Martínez-Lozano, Jorge Adolfo; Romano-Munive, Adriana Fabiola; Elizondo-Rivera, Javier; Téllez-Ávila, Félix Ignacio

doi:10.1016/j.rgmx.2017.03.007

Cited by 2 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Similar low prevalence of 0.24% was recorded in Lebanon, which was also conducted in one hospital centre in time period of ten years. 11 Regarding the patients age and sex, our findings are similar to international studies. All of them have a consensus that BE is more common in male patients with mean age higher than 50 years.…”

Section: Discussionsupporting

confidence: 90%

“…All of them have a consensus that BE is more common in male patients with mean age higher than 50 years. [6][7][8][9][10][11] BMI of BE patients with or without dysplasia showed that most of the patients are overweight with average BMI of 27.14. Some studies connected BMI with length of BE.…”

Section: Discussionmentioning

confidence: 99%

“…The grade of dysplasia was also the same, with higher number of low dysplasia and lower numbers of high dysplasia and adenocarcinoma. [6][7][8][9][10][11] It is safe to say that our standard of care of BE patients is up to date with current guidelines for BE 1 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnosis of Barrett's Esophagus in University Hospital Centre Zagreb Between 2012 and 2017

et al. 2019

View full text Add to dashboard Cite

To evaluate epidemiology and demographic data of patients diagnosed with Barrett's esophagus in University Hospital Centre Zagreb between January 2012 and December 2017. MATERIALS AND METHODS In a 6 year period, upper GI endoscopy was performed in 19950 patients. We have analysed endoscopy and hospital database regarding pathohistological confirmation and demographic data of patients diagnosed with Barrett's esophagus. RESULTS Endoscopy suspicion of esophageal metaplasia (ESEM) was made in 592 patients. Pathohistological confirmation of Barrett's esophagus was established in 163 patients (0.8%). Intestinal metaplasia

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis of Barrett's Esophagus in University Hospital Centre Zagreb Between 2012 and 2017

et al. 2019

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Pretreatment platelet/lymphocyte ratio (PLR) is a significant predictive marker for EGFR targeted therapy in patients with non-small-cell lung cancer

Zhang

Tan

Jiang

et al. 2019

Preprint

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutation is benefited from targeted therapy. There is no other superior predictive factor for targeted therapy except EGFR in the clinical. In this study, we analyzed the effect of pretreatment platelet/lymphocyte ratio (PLR) in NSCLC patients. In the present study, a total of 96 patients with EGFR mutations were included in this study. All patients received EGFR targeted therapy, until disease progression, unacceptable toxicity or other factors. The following evaluation was conducted about 3 days before initial treatment: detailed clinical history, physical examination, radiographic results, pathological diagnosis and laboratory parameters including complete blood cell counts and albumin levels. We found that pretreatment PLR is significantly associated to the PFS of NSCLC patients with EGFR targeted therapy. Patients in the PLR ≥190 group had shorter PFS than those in the PLR <190 group (P= 0.009). Furthermore, the 1-year PFS rate in the PLR ≥190 group were inferior to the low value group (P= 0.016). Multivariate analysis confirmed the role of PLR on predicting the efficacy of targeted therapy for advanced NSCLC. In addition, we found that PLR was also an predictive biomarker for grade 3/4 adverse events of diarrhea. In conclusion, high pretreatment PLR was an independent indicator for predicting a poor PFS for NSCLC patients receiving EGFR-TKIs treatment. Further studies are needed to identify the impact of PLR on results of EGFR-TKIs treatment.

show abstract

Esófago de Barrett: experiencia de 10 años en un centro de tercer nivel en México

Cited by 2 publications

References 13 publications

Diagnosis of Barrett's Esophagus in University Hospital Centre Zagreb Between 2012 and 2017

Diagnosis of Barrett's Esophagus in University Hospital Centre Zagreb Between 2012 and 2017

Pretreatment platelet/lymphocyte ratio (PLR) is a significant predictive marker for EGFR targeted therapy in patients with non-small-cell lung cancer

Contact Info

Product

Resources

About